The safety and efficacy of NEPA (netupitant and palonosetron) in the treatment of chemotherapy-induced nausea and vomiting

References

• Bloechl-Daum B, Deuson RR, Mavros P, et al. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24:4472–4478. doi:10.1200/JCO.2006.05.6382.
   PubMed Web of Science ®Google Scholar
• Cohen L, de Moor CA, Eisenberg P, et al. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer. 2007;15:497–503. doi:10.1007/s00520-006-0173-z.
   PubMed Web of Science ®Google Scholar
• Navari RM. Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents. Drugs. 2013;73:249–262. doi:10.1007/s40265-013-0019-1.
   PubMed Web of Science ®Google Scholar
• Navari RM. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Future Oncol. 2010;6:1074–1084. doi:10.2217/fon.10.74.
   Web of Science ®Google Scholar
• Navari RM. The current status of the use of palonosetron. Expert Opin Pharmacother. 2013;14:1281–1284. doi:10.1517/14656566.2013.799141.
   PubMed Web of Science ®Google Scholar
• Davis MP. New therapies for antiemetic prophylaxis for chemotherapy. J Comm Supp Oncol. 2016;14:11–20.
   PubMedGoogle Scholar
• Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21:232–243. doi:10.1093/annonc/mdp300.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Bohike K, Lyman GH, et al. Antiemetic American Society Clinical Oncology clinical practice guideline update. J Clin Oncol. 2016;34:381–386. doi:10.1200/JCO.2015.64.3635.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology version 2. Antiemesis: National Comprehensive Cancer Network (NCCN) [online]; 2016 [cited 2016 Apr]. Available from: http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf.
   Google Scholar
• Navari RM. Palonosetron for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2014;15:2588–2608. doi:10.1517/14656566.2014.972366.
   Web of Science ®Google Scholar
• Eglen RM, Lee CH, Smith W, et al. Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo. Br J Pharmacol. 1995;114:860–866.
   PubMed Web of Science ®Google Scholar
• Eisenberg P, MacKintosh FR, Ritch P, et al. Efficacy, safety, and pharmacokinetics of palonosetron in patients receiving highly emetogenic, cisplatin-based chemotherapy: a dose-ranging, clinical study. Ann Oncol. 2004;15:330–337.
   PubMed Web of Science ®Google Scholar
• Rojas C, Thomas AG, Alt J, et al. Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol. 2010;626:193–199. doi:10.1016/j.ejphar.2009.10.002.
   PubMed Web of Science ®Google Scholar
• Botrel T, Clark O, Clark L, et al. Efficacy of palonosetron compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic treatment: systematic review and meta-analysis. Support Care Cancer. 2011;19:823–832. doi:10.1007/s00520-010-0908-8.
   PubMed Web of Science ®Google Scholar
• Schwartzberg L, Barbour SY, Morrow GR, et al. Pooled analysis of phase III studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer. 2014;22:469–477. doi:10.1007/s00520-013-1999-9.
   PubMed Web of Science ®Google Scholar
• Popovic M, Warr DG, DeAngelis C, et al. Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer. 2014;22:1485–1497. doi:10.1007/s00520-013-2105-z.
   PubMed Web of Science ®Google Scholar
• Boccia R, Grunberg S, Franco-Gonzales E, et al. Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase III trial. Support Care Cancer. 2013;44:1453–1460. doi:10.1007/s00520-012-1691-5.
   Web of Science ®Google Scholar
• Diemunsch P, Grélot L. Potential of substance P antagonists as antiemetics. Drugs. 2000;60:533–546.
   PubMed Web of Science ®Google Scholar
• Rizzi A, Campi B, Camarda V, et al. In vitro and in vivo pharmacological characterization of the novel NK-1 receptor selective antagonist Netupitant. Peptides. 2012;37:86–97. doi:10.1016/j.peptides.2012.06.010.
   PubMed Web of Science ®Google Scholar
• Rossi G, Tilkola SO, Rudengren C, et al. A positron emission tomography study to assess the degree of neurokinin-1 receptor occupancy in the human brain after single doses of netupitant to healthy male subjects [abstract]. J Clin Oncol. 2012;30(Suppl):9054.
   Google Scholar
• Spinelli T, Calcagneli S, Giuliano C. Netupitant PET imaging and ADME studies in humans. J Clin Pharm. 2014;54:97–108. doi:10.1002/jcph.198.
   PubMed Web of Science ®Google Scholar
• Sankhala KK, Pandya DM, Sarantopoulos J, et al. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant. Expert Opin Drug Metab Toxicol. 2009;12:1607–1614. doi:10.1517/17425250903451675.
   Web of Science ®Google Scholar
• National Cancer Institute Drug Dictionary. Structure of aprepitant [Internet]. [ cited 2016 Mar 15]. Available from: http://www.cancer.gov/drugdictionary.
   Google Scholar
• Calcagnile S, Lanzarotti C, Rossi G, et al. Effect of netupitant, a highly selective NK-1 receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives. Support Care Cancer. 2013;21:2879–2887. doi:10.1007/s00520-013-1857-9.
   PubMed Web of Science ®Google Scholar
• Lanzarotti C, Rossi G. Effect of netupitant, a highly selective NK-1 receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone. Support Care Cancer. 2013;21:2783–2791. doi:10.1007/s00520-013-1855-y.
   PubMed Web of Science ®Google Scholar
• Shiran MR, Lennard MS, Iqbal MZ, et al. Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariants to the disposition of methadone in patients undergoing methadone maintenance treatment. Br J Pharmacol. 2009;67:29–37. doi:10.1111/j.1365-2125.2008.03312.x.
   Web of Science ®Google Scholar
• Soderberg Lofdal KC, Anderson MI, Gustafsson II. Cytochrome P-450 mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications. Drugs. 2013;73:533–543. doi:10.1007/s40265-013-0036-0.
   PubMed Web of Science ®Google Scholar
• Loue C, Tod M. Reliability and extension of quantitative prediction of CYP3A4 mediated drug interactions based on clinical data. AAPS J. 2014;16:1309–1320. doi:10.1208/s12248-014-9663-y.
   PubMed Web of Science ®Google Scholar
• Rojas C, Slusher BS. Pharmacological mechanisms of 5-HT3 tachykinin NK-1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol. 2012;684:1–7. doi:10.1016/j.ejphar.2012.01.046.
   PubMed Web of Science ®Google Scholar
• Stathis M, Pietra C, Rojas C, et al. Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects. Eur J Pharmacol. 2012;689:25–30. doi:10.1016/j.ejphar.2012.05.037.
   PubMed Web of Science ®Google Scholar
• Thomas AG, Stathis M, Rojas C, et al. Netupitant and palonosetron trigger NK-1 receptor internalization in NG108-15 cells. Exp Brain Res. 2014;232:2637–2644. doi:10.1007/s00221-014-4017-7.
   PubMed Web of Science ®Google Scholar
• Rojas C, Raje M, Tsukamoto T, et al. Molecular mechanisms of 5-HT3 and NK-1 receptor antagonists in prevention of emesis. Eur J Pharmacol. 2014;722:26–37. doi:10.1016/j.ejphar.2013.08.049.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Rossi G, Rizzi G, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014;25:1340–1346. doi:10.1093/annonc/mdu110.
   PubMed Web of Science ®Google Scholar
• Aapro M, Rugo H, Rossi G, et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol. 2014;25:1328–1333. doi:10.1093/annonc/mdu101.
   PubMed Web of Science ®Google Scholar
• Aapro M, Karthaus M, Schwartzberg LS, et al. Phase 3 study of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting during repeated moderately emetogenic chemotherapy cycles [abstract]. J Clin Oncol. 2014;32(Suppl 5):9502. doi:10.1200/JCO.2013.54.6911.
   Web of Science ®Google Scholar
• Gralla RJ, Bosnjak SM, Hontsa A, et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol. 2014;25:1333–1339. doi:10.1093/annonc/mdu096.
   PubMed Web of Science ®Google Scholar
• Schwartzberg L, Aapro M, Hesketh PJ, et al. Do NK-1 receptor antagonists contribute to nausea control? Evaluation of the novel NEPA fixed-dose combination of NK-1 receptor antagonist plus a 5-HT3 receptor antagonist from pivotal trials [abstract]. Support Care Cancer. 2014;22:S107–S161.
   Google Scholar
• FDA News Release. FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy. [ cited 2016 Mar]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements.
   Google Scholar
• Hesketh PJ, Aapro M, Jordan K, et al. A review of NEPA, a novel fixed antiemetic combination with the potential for enhancing guideline adherence and improving control of chemotherapy-induced nausea and vomiting. Biomed Res Int. 2015;2015:651879. Epub 2015 Sep 3. doi:10.1155/2015/651879.
   PubMed Web of Science ®Google Scholar